Clinical Trials Browser

Phase 2 × trametinib × Myeloid × Clear all

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Phase 2 Completed

21 enrolled 14 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic